Figures & data
Table 1. Overview of studies assessing response to SARS-CoV-2 vaccines in patients treated with secukinumab.
Furer V, Eviatar T, Zisman D, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis. 2021;80(10):1330–1338. Mahil SK, Bechman K, Raharja A, et al. The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study. The Lancet Rheumatology. 2021;3(9):e627–e37. Mahil SK, Bechman K, Raharja A, et al. Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study. Lancet Rheumatol. 2022;4(1):e42–e52. Damiani G, Allocco F, Malagoli P, Young Dermatologists Italian Network. COVID-19 vaccination and patients with psoriasis under biologics: real-life evidence on safety and effectiveness from italian vaccinated healthcare workers. Clin Exp Dermatol. 2021;46(6):1106–1108. Geisen UM, Berner DK, Tran F, et al. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis. 2021;80(10):1306–1311. Braun-Moscovici Y, Kaplan M, Braun M, et al. Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the pfizer mRNA vaccine against SARS-CoV-2. Ann Rheum Dis. 2021;80(10):1317–1321. Simon D, Tascilar K, Fagni F, et al. SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases. Ann Rheum Dis. 2021;80(10):1312–1316. Elkayam O, Eviatar T, Peleg H, et al. Humoral immunogenicity to a second and third doses of COVID-19 vaccine BNT162b2 in patients with spondyloarthritis receiving secukinumab: a prospective study [POS1244] Annals of the Rheumatic Diseases. 2022;81(Suppl 1):956. Smetanova J, Strizova Z, Sediva A, et al. Humoral and cellular immune responses to mRNA COVID-19 vaccines in patients with axial spondyloarthritis treated with adalimumab or secukinumab. Lancet Rheumatol. 2022;4(3):e163–e6. Al-Janabi A, Littlewood Z, Griffiths CEM, et al. Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease. Br J Dermatol. 2021;185(3):646–648. Benucci M, Damiani A, Infantino M, et al. Vaccination for SARS-CoV-2 in patients with psoriatic arthritis: can therapy affect the immunological response? Front Med. 2022;9:811829. Data availability statement
All data included in this review are available in the articles listed in references.